Original Publication Date: 1 October, 2014
Publication / Source: Hepatic Oncology
Authors: Chien-Jen Chen, Mei-Hsuan Lee, Jessica Liu, Hwai-I Yang
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, with more than 0.6 million deaths annually [1,2]. The incidence of liver cancer is highest in sub-Saharan Africa, and Central and Southeast Asia, where the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is high [1,2]. However, only a proportion of patients with chronic infection of HBV and/or HCV will develop HCC. The lifetime risk of developing HCC from 30 to 75 years, for men and women, was 27.38 and 7.99% in chronic hepatitis B patients, and 23.73 and 16.71% in chronic hepatitis C patients .